2024
Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapies Linked to Insurance Delays, Intravenous Infusions, and Lack of Pharmacy Support
Gottesman S, Xiao K, Nguyen H, Hernandez E, Saweris E, Jagannathan P, Jafri F, Davis J, Tong K, Tang Z, Gaidos J, Feagins L. Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapies Linked to Insurance Delays, Intravenous Infusions, and Lack of Pharmacy Support. Clinical And Translational Gastroenterology 2024, 16: e00808. PMID: 39718220, PMCID: PMC11932631, DOI: 10.14309/ctg.0000000000000808.Peer-Reviewed Original ResearchConceptsAdvanced therapiesRisk factorsMulticenter studyMulticenter study of patientsInflammatory bowel disease therapyStudy of patientsAdult inflammatory bowel diseasePatient-related factorsIntravenous drug deliverySmall molecule therapiesLogistic regression analysisInflammatory bowel diseaseBaseline demographicsDisease activityIntravenous infusionMolecule therapiesDisease characteristicsGastroenterology practiceTherapyBowel diseaseInsurance denialPatientsDoseIntravenous inductionCare teamImpact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
Sahyoun L, Fetene J, McMillan C, Protiva P, Al Bawardy B, Gaidos J, Proctor D. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease. Digestive Diseases And Sciences 2024, 69: 1654-1660. PMID: 38466459, DOI: 10.1007/s10620-024-08355-3.Peer-Reviewed Original ResearchSevere COVID-19 infectionInflammatory bowel diseaseCOVID-19 infectionIBD flareIBD therapyCOVID-19 treatmentSingle-center retrospective study of adult patientsMethodsA single-center retrospective studyAdvanced therapiesRetrospective study of adult patientsBowel diseaseStudy of adult patientsInflammatory bowel disease therapyDevelopment of severe COVID-19 infectionSevere COVID-19Acute COVID-19Corticosteroid useNo significant differenceNO therapyAdult patientsSupplemental oxygenPrimary outcomeSecondary outcomesTherapyCorticosteroids
2023
S1009 Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapy for Biologics Given Via Infusion Centers
Xiao K, Gottesman S, Nguyen H, Hernandez E, Anand T, Saweris E, Jaganathan P, Jafri F, Davis J, Tong K, Gaidos J, Feagins L. S1009 Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapy for Biologics Given Via Infusion Centers. The American Journal Of Gastroenterology 2023, 118: s764-s765. DOI: 10.14309/01.ajg.0000953676.10735.44.Peer-Reviewed Original Research
2019
830 Can CD74 Predict Treatment Response to Anti-TNF Agents in Inflammatory Bowel Disease?
Farr L, Bucala R, Moonah S. 830 Can CD74 Predict Treatment Response to Anti-TNF Agents in Inflammatory Bowel Disease? The American Journal Of Gastroenterology 2019, 114: s480-s480. DOI: 10.14309/01.ajg.0000592856.82828.b1.Peer-Reviewed Original ResearchCD74 deficient miceAnti-TNF failureAnti-TNF agentsDeficient miceIBD patientsInflammatory bowel disease therapyNormal wild-type miceSevere intestinal damageAnti-TNF drugsAnti-TNF therapyAnti-TNF treatmentManagement of IBDColitis mouse modelInflammatory bowel diseaseBody weight lossNormal drinking waterWild-type micePersonalized medicine approachEpithelial layer integrityTight junction markersColon shorteningDSS administrationMucosal healingMyeloperoxidase levelsBowel disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply